Welcome to Novo Nordisk Science Hub
The information on this website is intended for healthcare professionals only and is provided solely for the purpose of scientific exchange. By accessing this website you accept this legal disclaimer and you expressly confirm your status as a healthcare professional.
This website is not country specific and may therefore contain information that is not applicable to your country. The website is not intended to provide medical advice and/or treatment guidance. Therefore, before prescribing any product, always refer to information approved by regulatory authorities in your country such as the prescribing information and/or the Summary of Product Characteristics. Novo Nordisk accepts no liability for the accuracy, completeness or use of information on this website, and disclaims any liability to update the information contained on this website.
Dr. Julio Rosenstock is Director of Velocity Clinical Research at Medical City Dallas and Clinical Professor of Medicine at the University of Texas Southwestern Medical Center, Dallas, USA.
He received his MD from the University of Costa Rica School of Medicine, and completed fellowships in endocrinology and diabetes at the Royal Postgraduate Medical School, Hammersmith Hospital, London, UK and at the University of Texas Southwestern Medical Center, Dallas, USA. He is board certified in internal medicine, endocrinology and metabolism.
His clinical and research activities have focused on exploring novel agents and therapeutic strategies to improve glycemic control, particularly early combination therapies in type 2 diabetes. He has participated in hundreds of clinical trials and has been involved in developing new oral and injectable agents and insulin preparations, often acting as a lead clinical investigator and scientific advisor on the design and reporting of clinical trials on novel diabetes drugs.
He has authored or co-authored 360 peer-reviewed manuscripts (H-index 119) and hundreds of scientific abstracts and contributed to 13 book chapters on various diabetes topics. He is considered a key opinion leader in type 2 diabetes and has chaired or been a featured speaker at multiple lectures and presentations globally.
Professor Chantal Mathieu
University Hospital Gasthuisberg Leuven, Leuven, Belgium
Professor Chantal Mathieu is a physician-scientist who has contributed to the field of diabetes and endocrinology through basic and clinical research. Her basic research work focuses on pathogenesis and prevention of type 1 diabetes. Her clinical work involving new products and treatment paradigms in diabetes, such as new insulins, adjunct therapies and diagnosis of gestational diabetes, has made her a speaker in international fora. She coordinates the European project ‘INNODIA’ on biomarker discovery and intervention studies in type 1 diabetes. She is President of the European Association for the Study of Diabetes (EASD) and Vice-President of the European Diabetes Forum.
Read full bio
Professor Monika Kellerer
Department of Diabetology and Endocrinology, Angiology, Intensive Care Unit, Cardiology Marienhospital Stuttgart, Stuttgart, Germany
Professor Dr Monika Kellerer is Professor of Internal Medicine and Director of the Department of Diabetology, Endocrinology, Angiology, Intensive Care Unit and Cardiology at Marienhospital Stuttgart, a teaching hospital of the University of Tübingen, Germany.
She earned her MD degree from Ludwig-Maximilians University, Munich, Germany and her PhD (habilitation thesis) from Eberhard Karls University, Tübingen, Germany. She completed a post-doctoral fellowship at the Joslin Diabetes Center, Harvard Medical School, Boston, USA. She is board certified in endocrinology, diabetology and internal medicine by the German Physician Board.
She is 2021–2023 Senior President and Guideline Coordinator of the German Diabetes Association (DDG), and a member of the DDG board on scientific statements and healthcare policy. Her research interests are clinical diabetology, the insulin signalling mechanism, specific effects of insulin analogues, mechanisms of lipotoxicity and beta cell dysfunction. She is also involved in clinical research for diabetes as a national lead investigator.
She is the recipient of prestigious awards including the Förderpreis of the DDG (1992), the Ferdinand Bertram Award (1996) and the Helmut Otto Medal (2015). She has published numerous articles in medical literature and is the author or co-author of several books and book chapters in the field of diabetes.
Read full bio
Dr Athena Philis-Tsimikas
Corporate Vice President Scripps Whittier Diabetes Institute, San Diego, USA
Dr Athena Philis-Tsimikas, a board-certified endocrinologist, is Corporate Vice President of the Scripps Whittier Diabetes Institute at Scripps Health and Director of Community Engagement for the Clinical Translational Science Award, housed at Scripps Research Translational Institute in San Diego, USA (1UL1 TR002550-03, Topol PI). With over 25 years of experience, she has served as a member of the Scripps Clinic Medical Group in the division of endocrinology and diabetes and leads the diabetes care line for Scripps Health, which creates programmes, conducts research and delivers diabetes services across five Scripps hospitals, 25 outpatient facilities and the community.
She is a leader of the innovative Project Dulce and Dulce Digital programme, which cares for underserved populations with diabetes. Dr Philis-Tsimikas and Scripps Whittier Diabetes Institute are actively promoting participation of health centres in community-based clinical research, with a focus on integrating digital technologies to improve diabetes care in the ambulatory and hospital setting.
A complete list of her peer-reviewed publications can be found here: https://pubmed.ncbi.nlm.nih.gov/?term=philis-tsimikas+a.
Read full bio